Xofigo is Radium 223 Dichloride and is an alpha particle-emitting radioactive therapeutic agent. It is used for treatment of patient with prostate cancer.

Xofigo is suitable for metastatic castration-resistant prostate cancer (mCRPC) patient on second-generation hormonal therapy has:

• Bone metastases, and no visceral metastases

• Suspected disease progression:

— Increase in biomarker levels, such as prostate-specific antigen (PSA) and/or alkaline phosphatase (ALP)

— Progression seen on imaging scans

— Emerging symptoms (use of analgesics)

• Treatment plan: 6 injections total

• Slow intravenous (IV) injection over 1 minute

• Treatment can be completed in 5 months

• Patients may return home after the injection

ID and/or Passport. This original Preparation Instruction Sheet Previous/recent relevant reports or CD, if available. Previous / recent blood test results, if available.

DO NOT bring valuable belongings, including jewellery, etc

SPECIAL ARRANGEMENT

If patients are on wheel chair / trolley, please come with:

• Accompanying staff nurse familiar with patients' medical background

• Existing IV line / cannula, if any

• Urine bag, where applicable, should be emptied.

• Parking for ambulances are available at Level B2 carpark.

Urinal / bedpan / extra diapers when necessary for toileting care.